🔻 BREAKING: JAPAN JUST BECAME THE FIRST COUNTRY TO OFFICIALLY APPROVE MEDBED TECHNOLOGY FOR PUBLIC HOSPITALS. THE MEDIA BLACKOUT IS TOTAL.
July 17, 2026. Tokyo, Japan.
The Japanese Ministry of Health, Labour and Welfare just issued Directive MHLW-2026-7714: "Authorization of Electromagnetic Frequency Regeneration Devices for Clinical Deployment in National Healthcare Facilities."
This is not a trial. This is not a study. This is FULL APPROVAL.
Starting September 1, 2026, electromagnetic frequency regeneration chambers will be installed in 340 national hospitals across Japan.
⟁
WHY JAPAN FIRST:
Japan has the oldest population on Earth. 29.1% of their citizens are over 65. Their healthcare system is collapsing under the weight of chronic disease management.
In 2024, Japan spent $542 billion on healthcare — 80% of it on managing diseases that frequency technology can eliminate in a single session.
Their government did the math:
▪️ Cost of managing one cancer patient for life: $380,000
▪️ Cost of one MedBed session: $47 (electricity + maintenance)
▪️ Savings per patient: $379,953
▪️ Savings across population: $430 BILLION per year
Japan chose economics over pharmaceutical loyalty. They chose survival over suppression.
⟁
THE TECHNOLOGY APPROVED:
Directive MHLW-2026-7714 specifically authorizes three types of devices:
▪️ Type I — PEMF Regeneration Chamber: Full-body pulsed electromagnetic field therapy at 7.83-14.1 Hz for cellular regeneration. Approved for: cancer, organ failure, autoimmune disorders.
▪️ Type II — Torsion Field DNA Repair Unit: Targeted DNA correction using scalar wave technology at 528 Hz. Approved for: genetic disorders, aging reversal, neurological damage.
▪️ Type III — Biophotonic Coherence Restorer: Full-spectrum light frequency therapy for immune system restoration. Approved for: chronic infections, post-surgical recovery, radiation damage.
All three are what we have been calling MedBeds.
Japan just gave them official medical classification numbers.
⟁
THE PHARMACEUTICAL RESPONSE:
Within 3 hours of the announcement:
▪️ Pfizer Japan issued a formal protest to the Ministry of Health
▪️ Takeda Pharmaceutical stock dropped 11% on the Tokyo Stock Exchange
▪️ Astellas Pharma emergency board meeting — CEO resignation rumored
▪️ The Japan Pharmaceutical Manufacturers Association called it "reckless endangerment of public health"
They called CURING PEOPLE "endangerment of public health."
Read that again. Let it sink in.
Their definition of "public health" is: people staying sick and paying forever.
⟁
THE MEDIA BLACKOUT:
Search "Japan MedBed approval" on Google right now. You will find NOTHING.
Not CNN. Not BBC. Not Reuters. Not AP. Nothing.
A G7 nation just approved the most revolutionary medical technology in human history — and every single Western media outlet is pretending it didn't happen.
This is not negligence. This is coordinated suppression.
The pharmaceutical industry spends $6.58 billion per year on media advertising in the United States alone. That money doesn't just buy ad space. It buys silence.
⟁
WHAT THIS MEANS FOR YOU:
Japan is the crack in the dam.
Once one G7 nation approves it, the others cannot maintain the lie. The pressure becomes impossible. The science is now officially validated by one of the world's most advanced healthcare systems.
The timeline just accelerated:
▪️ Japan: Approved July 2026
▪️ South Korea: Expected approval August 2026
▪️ India: Already in advanced trials — approval expected Q4 2026
▪️ United States: Executive Order signed — civilian deployment within 120 days
▪️ EU: Under pressure — cannot ignore Japan's data
The dominoes are falling. One by one. Nation by nation.
They held the line for 61 years. Japan just broke it.
♟ The first country said YES. The rest will follow. The pharmaceutical era is over. The frequency era has begun. Japan lit the match.
Share this. The blackout only works if you stay silent.
MedBedsTechnologyNews
IVERMECTIN: FULL DOSAGE SCHEDULE FOR CANCER & PREVENTION
1000s of people use Dr. William Makis MD’s IVERMECTIN dosing chart. Here’s a clear, categorized breakdown based on body weight (mg/kg per day).
LOW DOSE: ≤ 0.5 mg/kg/day
**Best for:**
- Cancers in remission
- Strong family history or genetic predisposition
- Prophylaxis (preventive)
**Side effects:** No long-term side effects reported.
**Example:** Dr. Tess Lawrie reported a Stage 3 ovarian cancer case treated with chemo + 12 mg ivermectin daily. Tumor marker CA125 dropped from 288 to 22 after 2 months and the tumor vanished.
MEDIUM DOSE: 1.0 mg/kg/day
**Best for:** Starting dose for **most cancers** (lung, pancreatic, renal cell, gastric, etc.).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Shankara Chetty’s 70-year-old prostate cancer patient (PSA 89) took 45 mg/day (plus lactoferrin). After two months PSA fell to 10.9.
HIGH DOSE: 2.0 mg/kg/day
**Best for:** Very aggressive cancers (leukemia, pancreatic, brain cancers).
**Side effects:** No long-term side effects reported.
**Example:** Dr. Allan Landrito’s Stage 4 gallbladder cancer patient took 2 mg/kg daily for 14 months — cancer disappeared.
VERY HIGH DOSE: ≥ 2.5 mg/kg/day
**Best for:** Extensive metastatic disease, extremely poor prognosis, or certain brain cancers.
**Side effects:** Possible short-term & transient visual effects (usually resolve in a few days).
**Example:** Dr. Shankara Chetty treated a patient with 2.5 mg/kg/day — no side effects reported.
**Quick conversion example (for a 60 kg / 132 lb person):**
- Low: ≤30 mg/day
- Medium: 60 mg/day (≈5×12 mg tablets or 1 teaspoon liquid)
- High: 120 mg/day
- Very High: ≥150 mg/day
Many anecdotal reports exist of long-term daily use (months to over a year) with no serious toxicity, but individual responses vary.
Always work with a knowledgeable clinician, especially if you have pre-existing conditions (e.g., vision issues or glaucoma). This is for educational purposes only.
Share to spread awareness — information. Follow for more .